<DOC>
	<DOCNO>NCT02700373</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , single ascend dose study assess safety tolerability PDC-APB intramuscular ( IM ) injection compare placebo .</brief_summary>
	<brief_title>A Phase I , Single-Center Study PDC-APB Healthy Volunteers</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , single ascend dose study assess safety tolerability PDC-APB intramuscular ( IM ) injection compare placebo . In First-in-Human study anticipate 5 dose level ( 2.5 mg , 10 mg , 0.125 mg 1.0 mg PDC-APB ) study sequential cohort . Each cohort enroll 8 subject , 6 subject randomize active treatment 2 randomize placebo , double-blind manner . A sentinel group 2 subject cohort randomize active ( 1 subject ) placebo ( 1 subject ) . If dose tolerate sentinel group , remain 6 subject cohort treat ( 5 active 1 placebo ) . Safety assess cohort start treatment next high dose level . If study treatment tolerate finding necessitate stopping study , next cohort treat next high dose level , manner . This process continue high intend dose ( 1 mL ) reach , side effect limit dose escalation observe .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Contact</mesh_term>
	<criteria>Subjects require meet follow criterion order include study : 1 . Healthy male female subject determine medical history physical examination , 18 55 year age , inclusive 2 . History previous exposure poison ivy , oak , sumac without development significant contact dermatitis . Significant contact dermatitis define skin reaction cover 10 % body surface area subject 's estimation , occur face genitals , rat subject moderate severe , require treatment topical , oral , injectable ( systemic ) steroid resolution symptom . History exposure document use Allergic Contact Dermatitis Questionnaire ( Appendix 1 ) . 3 . For female subject : Surgically sterile menopausal ( least 1 year absence vaginal bleeding spot ) confirm folliclestimulating hormone ( FSH ) ≥ 40 mIU/mL . Females childbearing age/potential may include provide use medically acceptable method birth control 1 month prior duration study 3 month thereafter . Dual method must use , example hormonal method use barrier method . 4 . For male subject partner childbearing potential : Willing use two method contraception , one must barrier method , duration study 3 month last dose study drug , agree donate sperm 3 month last dose study drug 5 . A body mass index ( BMI ) 18 32 kg/m2 inclusive 6 . Able participate willing give write informed consent comply study restriction 1 . History significant contact dermatitis secondary exposure poison ivy , poison oak , poison sumac , define Inclusion Criteria # 2 ( ) 2 . Positive breath test alcohol urine test drug abuse per local standard screening , history alcohol drug abuse within past 24 month 3 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) , HIV clinical laboratory test 4 . Administration , need , prescription drug within 21 day , overthecounter drug ( except acetaminophen ibuprofen ≤ 1 g/day multivitamin , permit ) 5 . Any screening laboratory evaluation outside laboratory reference range judge investigator clinically significant ( include hepatic renal panel , complete blood count , chemistry panel , urinalysis ) 6 . History significant renal urinary disease active symptom renal urinary disease . A history renal stone urinary tract infection exclude subject . 7 . History significant hepatic disease impairment , active symptom hepatic disease 8 . Presence clinically significant gastrointestinal ( GI ) disorder symptom active GI disease . A history appendectomy cholecystectomy exclude subject . 9 . History significant cardiovascular disease , hypertension require drug therapy , congestive heart failure , stroke , angina , arrhythmia , symptom sign active cardiovascular disease , clinically significant abnormality screen ECG Sponsor considers unacceptable 10 . History significant psychiatric disease , include limited : bipolar disorder , depression , anxiety , panic attack , schizophrenia 11 . History symptom significant central nervous system ( CNS ) disease , include limited : transient ischemic attack ( TIA ) , stroke , seizure disorder , history loss consciousness head trauma , behavioral disturbance 12 . History suicide attempt report suicidal ideation 13 . Concomitant disease organ system condition abnormality could pose unacceptable risk subject study , opinion investigator , base possible interference absorption , distribution , metabolism , elimination study drug possible effect study drug condition abnormality 14 . History significant allergy require treatment steroid ( topical oral administration ) , use previous year immunosuppressant immunotherapy , use oral topical antihistamine previous 14 day 15 . Known suspected allergy cutaneous sensitivity product component , include sesame sesame oil , benzyl alcohol , ethanol 16 . History asthma , include subject asthma require acute maintenance inhale oral steroid use control symptom , well subject intermittent astham require corticosteroid . 17 . Participation investigational drug device study within 30 day prior screen 18 . Donation blood 400 mL within 60 day prior screen and/or hemoglobin &lt; 7 mmol/L , plasma donation within 7 day prior screen 19 . Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>